Brief: Paion To Market Byfavo In United States By End-202

PAION AG

06/10/2020 16:25

Oct 6 (Reuters) - PAION AG  PA8G.DE :
    * REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE
ACACIA IN THE U.S.
    * BYFAVO DESIGNATED AS A SCHEDULE IV MEDICINE BY DRUG
ENFORCEMENT
ADMINISTRATION
    * BYFAVO EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S.
BEFORE END
OF 2020
    * LICENSEE ACACIA CLEARS FINAL HURDLE ON PATH TO COMMERCIAL
LAUNCH
IN U.S.

Source text for Eikon:  ID:nEQ9B56GQa 
Further company coverage:  PA8G.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))